CBER Approvals Hit A High Note For Director Midthun's Swan Song

Novel approvals from FDA's Center for Biologics Evaluation and Research grew for a fourth consecutive year in 2015, sending off retiring center director Karen Midthun with a record high count of 12 new biologics.

While CBER has at times been known for rocky review performance, consistent gains over the last three years suggest that...